e-learning
resources
ERJ
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
WHO 2019 guidelines on drug-resistant tuberculosis treatment: based on evidence or expert opinion?
Lorenzo Guglielmetti, Helena Huerga, Uzma Khan, Francis Varaine
Source:
Eur Respir J, 55 (3) 1901935; 10.1183/13993003.01935-2019
Journal Issue:
March
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Lorenzo Guglielmetti, Helena Huerga, Uzma Khan, Francis Varaine. WHO 2019 guidelines on drug-resistant tuberculosis treatment: based on evidence or expert opinion?. Eur Respir J, 55 (3) 1901935; 10.1183/13993003.01935-2019
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Current approaches to formulate evidence-based recommendations: a case study of WHO drug-resistant tuberculosis treatment guidance
Source: International Congress 2018 – Drug-resistant tuberculosis
Year: 2018
WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update
Source: Eur Respir J 2011; 38: 516-528
Year: 2011
Monitoring toxicity in individuals receiving treatment for latent tuberculosis infection: a systematic review versus expert opinion
Source: Eur Respir J 2015; 45: 1170-1173
Year: 2015
The impact of national recommendations on antibiotic treatment of community acquired pneumonia. Do pediatricians follow the national guidelines?
Source: International Congress 2017 – Pulmonary infection and inflammation
Year: 2017
Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement
Source: Eur Respir J 2014; 44: 23-63
Year: 2014
The ERS-endorsed official ATS/CDC/IDSA clinical practice guidelines on treatment of drug-susceptible tuberculosis
Source: Eur Respir J 2016; 48: 963-971
Year: 2016
Is there enough evidence to support recommendations on tuberculosis control?
Source: Annual Congress 2008 - Clinical epidemiology of tuberculosis
Year: 2008
Getting the best possible evidence from observational studies of treatment of multidrug-resistant tuberculosis patients
Source: Annual Congress 2013 –Drug-resistant tuberculosis: new clinical and public health insights
Year: 2013
From international guidelines to local guidelines for nosocomial pneumonia: what is missing?
Source: International Congress 2019 – Multidrug resistance in nosocomial pneumonia: burden, magnitude and solution
Year: 2019
Epidemiology and clinical management of XDR-TB: a systematic review by TBNET
Source: Eur Respir J 2009; 33: 871-881
Year: 2009
The WHO Guidelines for the Programmatic Management of drug-resistant TB: the 2011 update - recommendations and evidence
Source: Annual Congress 2011 - ECDC and WHO tuberculosis guidelines: update 2011 (organised within the FP7 funded TB-PAN-NET project)
Year: 2011
Multidrug-resistant tuberculosis and beyond: an updated analysis of the current evidence on bedaquiline
Source: Eur Respir J , 49 (3) 1700146; DOI: 10.1183/13993003.00146-2017
Year: 2017
A clinical and aetiological evaluation of community acquired pneumonia-are we following guidelines in prescribing antibiotics?
Source: Annual Congress 2009 - Aetiology and treatment of community-acquired pneumonia
Year: 2009
WHO guidance on multidrug-resistant tuberculosis treatment: using and communicating the evidence
Source: Eur Respir J, 55 (3) 1902325; 10.1183/13993003.02325-2019
Year: 2020
The new ATS/ERS/IDSA/CDC guidelines for MDR-TB: rationale, methods and recommendations
Source: International Congress 2019 – Managing drug-resistant tuberculosis: from new guidelines to clinical practice
Year: 2019
Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline
Source: Guideline 2020
Year: 2020
Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline
Source: Eur Respir J, 56 (1) 2000535; 10.1183/13993003.00535-2020
Year: 2020
Definition of COPD: based on evidence or opinion?
Source: Eur Respir J 2008; 31: 681-682
Year: 2008
Are TB services in England adhering to new NICE guidelines on screening for latent TB?
Source: International Congress 2017 – Migrants and screening
Year: 2017
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept